1411 ET - Elevance Health cut its guidance by slightly more than expected, but still within the realm of possibilities investors anticipated, Guggenheim analysts say in a note. Shares could be volatile given the updated outlook, but in the longer term, the new $30 2025 adjusted EPS baseline should give the stock a more attractive jump-off for next year, given the importance of health insurance exchange repricing and normalizing Medicaid costs for the company's long-term earnings growth target, the analysts say. Elevance slides 11%. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
July 17, 2025 14:11 ET (18:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。